Since the early observations of Elie Metchnikoff, a wealth of experiments have described the use of selected microorganisms, mainly belonging to the lactic acid bacteria family, for the prevention or treatment of a variety of pathological situations. Nevertheless, the mechanisms underlying the proposed actions remain vastly unknown, partly as a consequence of the complexity of the gastro-intestinal ecosystem with which these biotherapeutic agents are expected to interact, but also because of the increasing variety of strains considered to have potential probiotic characteristics. During the past decades, however, the beneficial effect of specific strains in preventing or treating intestinal disorders has been substantiated by well-controlled clinical trials. Increasing evidence, including human studies, is also supporting the immunomodulatory role attributed to given lactic acid bacterial strains. The desire by consumers to use natural methods for health maintenance rather than long-term chemotherapeutic agents (i.e. antibiotics), linked to their expectation that food becomes a source of prolonged well-being, supports the speculation that the probiotic market will expand rapidly. Much of this growth will also depend on the reliability of claims that these products will bare. Therefore, the legislator will have to provide clear rules and regulations which will depend on measurable biomarkers and criteria based on scientific evidence. These commercial and legislative needs will hopefully provide scientists with the resources necessary to conduct the multidisciplinary research required to establish facts and mechanisms of action for carefully selected probiotic strains. These research results will probably be as essential for the positioning of probiotic preparations as either a food, a food supplement or as pharmaceutical preparation.
INTRODUCTION
Dietary lactic acid bacteria (LAB) are mostly known for their widespread use in the preparation of fermented food and feed products. Yet, the health promoting effect that specific strains or species of this family of bacteria may exert in human or animals has also been the matter of active investigation over the past century. Despite its potential socio-economic impact, the research associated with probiotics has remained quite weak over many decades [1, 2] . Even though recent clinical trials have substantiated given effects, the mechanisms underlying the studied health beneficial actions remain vastly unknown. Only few examples exist where lactic acid bacteria have been attributed reliable pharmaceutical properties (for reviews see [3] [4] [5] [6] ). Today, the probiotic area is benefiting from the interest of both the industry and scientists skilled in the multiple disciplines necessary to cover this complex research domain.
*Address correspondence to this author at the Laboratory of Bacteriology of Ecosystems, INSERM IFR17, Institut Pasteur de Lille, France; Ph.: (33) 320 87 11 86 ; Fax: (33) 320 87 11 92 It is foreseen that the availability of modern molecular tools will, in the next future, help to provide sound scientific basis for the claimed health effects.
An impressive number of reviews and books have reported the constantly evolving knowledge and state of the art in probiotics [1, 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . With this paper we like to stress the multidisciplinary complexity of the probiotic research field and address the existing cross-correlation between a number of key issues in the field. The development of successful probiotic products will rely on clear interdisciplinary research strategies which will make use of-and try to link the wealth of information already available.
HISTORY AND PRESENT SITUATION
Since the early observations of Elie Metchnikoff, the beneficial effects of LAB in human and animal health have been investigated. Almost a century ago, this Nobel Prize Winner suggested that the long healthy life of Bulgarian peasants resulted from their consumption of fermented milk products. He believed that when consumed, the fermenting bacillus (Lactobacillus) positively influenced the microflora of the gut, decreasing "putrefaction" and toxic microbial activities there. E. Metchnikoff established that bacteria are Lactobacillus acidophilus CK120 Matsutani Chemical Product (Japan)
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Arla (Sweden) not necessarily detrimental to man but may, on the contrary, play an important role in our well-being. He was the first to recommend ingestion of live cultures of beneficial microorganisms such as the LAB [27, 28] . Metchnikoff's theory thus gave birth to the concept of 'probiotic' "avant la lettre". It is, however, much later that the word 'pro-biotic' (pro-"bios", i.e. pro-life) was proposed by Parker [29] for "organisms and substances which contribute to intestinal microbial balance".
The positive effect of probiotics on the intestinal ecosystem of its consumer is also implicit in the definition given by Füller in 1989 . According to this author, "a probiotic is a live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance" [30] . Although referring to the supplementation of animal feeds, today the definition applies also to the human situation and has been recently reformulated by Guarner and Schaafsma as "living microorganisms, which upon ingestion in certain numbers, exert health benefits on the host beyond inherent basic nutrition" [31] . Over the years, many other definitions have been proposed [4, [32] [33] [34] [35] but none of them has received universal acceptance. Delicate points of discussion relate to the site of activity (oral cavity, upper GI tract, lower GI tract, vagina, skin,…), the viability of the probiotic strain (dead cells, alive upon digestion, alive at the activity site), the concentration of cells necessary to exert the specified probiotic effect, the use of mono-or mixed cultures, the format of intake and its carrier (food (dairy) products, food supplements, pharmaceutical preparations (powders, tablets or encapsulated powders), etc…), and its functionality beyond the inherent basic nutrition (influence on the nutritional balance; effect on the indigenous microflora balance; effect on the intestinal physiology; effect on the mucosal and systemic immune system). Related to functionality, the discussion is also focusing on the importance of characteristics such as adhesion, translocation, implantation, local compartment, etc. The lack of proper biomarkers and/or technologies to directly quantify the presence or efficacy of (potential) probiotic strains is often the cause of these ongoing discussions. Also the fact that many claimed probiotic benefits are related to prevention rather than therapy makes reliable definition difficult. As a consequence the difference between basic food grade LAB and "true probiotic" LAB is not very clear in all cases. Still, it is generally accepted that not all LAB have probiotic properties.
Positive health effects have also been described for "prebiotics" which were defined by Gibson & Roberfroid as "non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth, activity or both, of one or a limited number of bacterial species already resident in the colon" [36] . The prebiotic field corresponds also to an active area of research as described in recent reviews (see for example [9, [36] [37] [38] ). The expression "synbiotic" designates the synergistic combination of preand probiotics, a concept which looks most promising but still remains in its infancy [38] .
Today, the major consumption of probiotics by humans in Europe is in the form of dairy-based foods containing mainly lactobacilli and/or bifidobacteria, even though some probiotic preparations are based on Enterococcus strains or yeasts such as Saccharomyces boulardii ( Table 1) . A s mentioned above, probiotics are also available to the consumers as powders or tablets that, at least in the USA, like the milk-based products, are mostly obtained from retail outlets, usually supermarkets, grocery-and health food stores. This is in contrast with the impressive list of therapeutic and prophylactic properties attributed to the LAB (see below) which are related to health benefit and thus, to medical science. Yet, the studies on probiotics have not been conducted in the past with the same logic as that used for the development of modern therapeutic drugs. In particular, pharmacokinetic approaches have mostly been neglected [2, 14] .
Still, an onset to enter the clinical or pharmaceutical field can be noticed, as an increased variety of "over the counter" (OTC) products becomes available from the pharmacist. Many, but not all of these products have gone through a registration procedure, which, however, is not always comparable to the procedure required for modern therapeutic drugs.
In the food industry, the commercialization of probiotics is regulated by the normal legislation on foods with respect to the packaging and labeling of fresh food products. In this legislation no claims related to health, prevention and curing are allowed. This is in contrast to e.g. Japan where a specific 'FOSHU label' can be requested (see below).
THE GASTRO-INTESTINAL ECOSYSTEM AND THE WELL-BEING
After the respiratory tract, the gastro-intestinal (GI) tract constitutes the second largest body surface area, described to be around 250 m 2 . In addition to the enormous quantity of food which passes through this canal (about 60 tons during a normal lifetime), the GI surfaces are continuously challenged by a number of chemicals, including pharmaceutical preparations and correspond to the entry site of most pathogenic microorganisms. As such, the mucosal surfaces, composed of a mono-layer of epithelial cells covered by mucus, represent the first line of defense against bacterial toxins and infections caused by bacteria, viruses or parasites. Moreover, they are the target of several disturbances induced by the modern lifestyle and "Western" food habits [11, 21, 22, 39] .
Therefore, the GI tract has developed into a sophisticated ecosystem whose balance in healthy individuals, is ensured by the subtle interaction between two major players, the GI microflora on the one hand and the GI-associated mucosal immune system on the other hand. In addition, a number of non-specific or physiological factors such as the mucus layer, peristaltism of the intestinal mucosa, rapid epithelium turnover, acidic and enzymatic environment, all participate in maintaining the integrity of the GI ecosystem. Today, the complexity of the GI microflora is well recognized. Colonization begins at birth and continues throughout life, leading to a very rich flora consisting of more than four hundred different species. Bacterial concentrations have been estimated to reach numbers (total CFU) that exceed by 10-fold the number of human cells associated with the human body [39] [40] [41] . It should be stressed, however, that the analysis of the intestinal microflora is still in its infancy and that our knowledge of this ecosystem is expected to progress notably with the aid of the recently developed molecular approaches [40] [41] [42] . Questions to be addressed are manifold. How stable is the flora over a lifetime? What is the influence of a varying transient flora on the resident flora? Can the resident flora be changed temporarily? For how long? What is the relation between diet and microbial ecosystem?
Despite the lack of clear answers to these questions, knowledge on the role of the microbial flora in relation to health is increasing rapidly. The protective roles of the indigenous microflora are believed to be multiple. Not only does it create a barrier effect against potential pathogens, a mechanism known as the "Nurmi concept" [43] , or as 'colonization resistance', but it also leads to improved integrity and reduced permeability of the mucosal epithelium. In addition, it contributes to the host defense by modulating and improving the homeostasis of its immune function [7, 8, 14, [16] [17] [18] [19] [21] [22] [23] which is a key issue as the mucosal surfaces are specialized in two opposite functions: tolerance to environmental antigens (such as dietary antigens, commensal microflora) and immunity to foreign antigens such as pathogenic microorganisms or toxins. In other words the immune system needs to discriminate between infection and non-infection, self and non-self, beneficial and harmful. The role of the gut microflora in the maturation of the mucosal immune barrier is regarded as predominant and expected to take place in the first years of life [44, 45, 46, 47] . It is suspected that the increasing incidence of allergic diseases, seen among children of industrialized countries, is connected to their difficulty to establish a satisfactory protective endogenous gut flora, possibly as a consequence of a lowered consumption of foods produced by natural fermentation [39, 44, 45] , along with a decreased contact with pathogens due to the increased hygienic conditions of modern housing [48] [49] [50] [51] . These modified food habits along with modern life styles and changed environmental conditions have been cited as causes of stress that predispose humans to inflammatory, ulcerative, degenerative, auto-immune and infectious diseases [39] . The latter constitute a major public health problem as the resistance to antimicrobial agents is constantly increasing and will necessitate the development of alternative strategies for the prevention of infections. The World Health Organization recently recommended to reduce the use of antibiotics both in human and animals and to increase efforts to prevent diseases by improving immunization coverage and reconsidering "older therapeutic approaches" such as bacterial interference [3, 39] . It is worth noting that both aspects are part of the probiotic applications presently under investigation.
Taken together these arguments underline the importance of the role played by beneficial bacteria in the gut and clearly show that probiotic preparations with proven effect would respond to the existing demand of low cost and low risk health functional ingredients. In the frame of the above listed causes of stress, it remains to be consolidated whether these beneficial bacteria can or should be part of normal healthy (daily) diet or whether they should also be available as therapeutic agents for the treatment of specific disease conditions.
T H E P O T E N T I A L H E A L T H B E N E F I T S A T T R I B U T E D T O P R O B I O T I C MICROORGANISMS
The list of potential health promoting traits attributed in particular to LAB is quite impressive ( Table 2) .
Nevertheless, as recognized unanimously, even though many of these effects are supported by progressively increasing evidence resulting from a variety of in vitro and animal studies, most of them remain to be substantiated by human randomized double-blind and placebo-controlled clinical studies. As summarized in the next section, the proven medical indications for probiotic use have been gained mainly in the case of the following gastrointestinal disturbances: lactose intolerance, antibiotic associated diarrhea, recurrence of relapsing diarrhea due to Clostridium difficile and shortening/reduction of rotavirus enteritis in children [53] . In addition, based on recent clinical studies, probiotics have been proposed as a novel approach in the management of allergic diseases, especially in infants [13] and in the treatment and prevention of inflammatory bowel diseases [53, 54] . Strikingly, while an important effort is presently being made to confirm or prove all other claimed health benefits, experiments to unravel the mechanisms underlying different actions are just starting. Notably, the analysis of the interaction of probiotic strains with different components of the immune system [7, 8, [16] [17] [18] 55] or with intestinal cell lines [26] has been actively initiated ( Table  3) .
As mentioned above, it is important to bear in mind that not all LAB strains exhibit 'probiotic' effects. Although it is tempting to speculate that one species will mediate specific effects, and that different strains of a particular species are expected to give comparable effects, research results do not support this conclusion. For many targets, individual strains of lactobacilli, bifidobacteria and other genera have all shown positive effects. As head-to-head comparison on strain-, species-or genus level are very rarely done, generalizations about probiotic performance on the genus and species level are impossible to make. The observed phenotypic and genotypic variability amongst isolates belonging to a well-established species make it impossible, at present, to generalize probiotic efficacy. It is also unlikely that a single strain will bear the multitude of proposed benefits. Natural evolution and adaptation processes have lead to a world-wide variation in survival strategies for bacteria. Depending on the niche where they have to establish (skin, stomach, intestine, vagina, …) one can expect a multitude of possible survival mechanisms, some 
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L. rhamnosus Mice (oral) Ex vivo phagocytosis of blood and peritoneal cells [202, 203] of which may be beneficial for the host ('probiotic'), while others may be detrimental ('pathogenic'). It is very unlikely that a single strain will have acquired all beneficial adaptations. Further research and development in probiotics will thus necessitate to set forward criteria for probiotic effects and to perform the necessary molecular analysis to measure and confirm the postulated physiological, metabolic, immunological and ecological effects. That is: probiotic research will need to use modern biological tools to identify the genetic determinants and the exact nature of events it involves. This could be achieved, for example, by comparing isogenic pairs of strains affected in a defined manner, in proposed probiotic activity factors such as adhesion, bacteriocin production, cell wall composition, etc… which are currently postulated to be mediators of specific health properties [12, 24, 56] . In addition, it will be crucial to establish validated functional models, preferably in vitro, that will allow proper pre-screening for probiotic strains exhibiting the desired property and lacking potentially harmful characteristics. This will rely, on the one hand, on the verification of a working hypothesis and, on the other hand, on the improved understanding of the correlation between the huge variety of in vitro tests, animal models and human studies that have been performed so far. The data generated until now were based on a multitude of systems, which differed at the level of the targeted effect, the probiotic candidate strain, the selected model or the read-out parameters. This has greatly obscured fundamental knowledge in the field.
As expected, variations in the probiotic response have also resulted from factors affecting the physiological conditions of the host or the quality of the probiotic product itself. Administration of levels too low to be effective, improper identification of the strains used and failure to validate counts of microbes in test products, have all contributed to difficulties in interpreting results [35] . So it is obvious that, despite the progress made over the last 10 years, still large gaps exist in our experimental set-ups. The lack of proper standards or limits describing the range in which microbial activities are considered pathogenic, commensal or probiotic, will continue to blur the practical applicability of the results obtained, no matter how reliable the models or technologies used are. The present lack of an accepted definition of 'probiotic' is a logical consequence of this lack of knowledge. Future research should therefore most probably not only focus on the development or testing of new 'probiotic' strains in existing models, but might benefit from the prior establishment of standardized, fully controlled model systems and reliable biomarkers for which the biological relevance has been established in a quantitative way. The real challenge for future research may be the final integration of different models dealing with metabolic, physiological, ecological and immunological aspects into a comprehensive strategy for setting up clinical trials for a specific target population in a defined clinical condition.
While our present understanding of the gut ecosystem is too fragmentary to precisely define the "normal" microbial balance, and given the impact a probiotic strain may have on the composition and function of the intestinal microflora [2, 12] , the perceived desirable qualities of probiotics are numerous [8, 12, 15, 26] . As shown in Table 4 , the expected beneficial characteristics of potential probiotic strains encompass besides the physiological, immunological, metabolic and genetic traits, also, importantly, technological properties. The implementation of a functionally active strain in the final probiotic food or product will indeed determine whether or not the strain is utilized at its full potential. It is moreover recommended that each potential probiotic strain (in its final formulation) be documented and assessed independently, with results preferably confirmed by independent research groups. Extrapolation of data from closely related strains should therefore be considered as non-acceptable [8] .
CLINICAL TRIALS: PRESENT STATUS
Many of the indications for probiotic activity have been obtained from effects observed in various clinical situations. The tentative list of possible applications is depicted in Table 2 . Even though there are presently few strains that have officially gained the status of pharmaceutical preparation, each of these effects is gradually being supported by a number of clinical studies or human intervention trials, performed in a way that resembles the traditional pharmacological approach (placebo-controlled, double blind, randomized trials). The strains used in these studies ( Table 1) belong to different microbial species, but are mostly lactic acid bacteria.
The therapeutic use of probiotics has been considered as successful in the cases of lactose intolerance, certain diarrheal diseases, inflammatory bowel disease (IBD) and atopic eczema. Positive indications have been obtained (and which still need to be reinforced) for irritable bowel syndrome (IBS), colon cancer, travellers diarrhea and H. pylori infection. In contrast, insufficient proof has been provided for some effects on viral infections or blood cholesterol reduction. A brief update of the human intervention trials applied to these different diseases is given below.
A. Lactose Intolerance
Lactose intolerance occurs with approx. 70% of the population worldwide, except in babies where primary intolerance is almost non-existing. The clinical importance of lactose intolerance is most predominant in young children, and is often revealed by acidic diarrhea and feces containing reducing sugars. In adults, the digestive symptoms are less severe: abdominal pain, cramps, or flatulence. Moreover, secondary lactose intolerance is often observed in patients with bowel resection or enteritis [57] .
It has been clearly shown that yogurt improves the absorption of lactose in lactase deficient patients and can limit the digestive symptoms [58] [59] [60] [61] [62] . Optimal effect is obtained after the intake of live bacteria, selected for their active beta-galactosidase capacity [63] [64] [65] . Thermal treatment of the fermented product may inhibit the LAB and their lactase. A second mechanism of action has been described as a delayed intestinal delivery of lactose after yogurt consumption, as compared to normal milk intake, due to the viscous texture of yogurt [61, 66] .
B. Antibiotic Associated Diarrhea (AAD)
Approximately 20% of the patients treated with antibiotics will develop AAD because their intestinal flora, responsible for the natural colonization resistance, is disturbed or reduced. The intestinal flora modification (in particular in the LAB population) could be the cause of diarrhea, dehydration and electrolytic imbalance. Also, the fermentation in the colon can be reduced. Many preparations have been tested for their preventive efficacy against AAD [67] [68] [69] [70] . However, more studies need to be performed using well controlled conditions and strains, before we can finally understand which prophylactic probiotics should be taken against secondary effects of specific antibiotics, applied at a specific dose in a specific type of patient.
C. Gastro-enteritis
Causes of gastro-enteritis can be viral, bacterial or parasitic. Even though gastro-enteritis is the main cause of acute diarrhea, a spontaneous recovery within a few days is most common. Treatment is usually restricted to the use of oral rehydration solutions and therefore antibiotic treatment is rarely needed. The use of probiotics, however, could be considered from a preventive point of view (for reviews see [3, 71] ).
-Rotavirus Gastro-enteritis in Children
Several studies have aimed at quantifying the effect of LAB containing preparations on infantile diarrhea with changing success [72] [73] [74] [75] [76] [77] [78] [79] . Most successful were the studies related to the prevention and treatment of rotavirus diarrhea by the strain Lactobacillus rhamnosus GG. This strain has been used repeatedly to reduce the duration of the acute diarrhea significantly [80] [81] [82] [83] [84] [85] [86] [87] [88] . Similar successes have been described for other strains, including Lb. casei Shirota [89] , Enterococcus faecium SF 68 [6, [90] [91] [92] and even yogurt [74] .
Regarding prevention of rotavirus, the most well-known study was performed by Saavedra et al. on long-term hospitalized infants. In a double-blind placebo-controlled trial, the authors found that Streptococcus thermophilus and Bifidobacterium bifidum could significantly reduce the risk of diarrhea (7% cases with probiotic versus 31% in the control group) and the shedding of rotavirus (10% shedding with probiotic versus 39% in the control group) [5] .
-Clostridium Difficile Infection after Antibiotic Treatment
Clostridium difficile infections are often found to be recurrent in older patients. It is estimated that about 20% of the patients treated for the first infection will experience relapse of C. difficile infection, and up to 40% after subsequent treatments. Several studies were performed which suggest a potential therapeutic role of different probiotic strains, including Saccharomyces boulardii [93] [94] [95] [96] [97] [98] [99] . These indications, however, may require some confirmation in a randomized controlled trial.
D. Bacterial Overgrowth
Some studies have indicated that mild bacterial overgrowth can be treated with lactobacilli [100, 101] , while Saccharomyces boulardii was found to be ineffective [101] . The latter, however, was able to reduce the duration of diarrhea induced by tube feeding [102] [103] [104] . Diarrhea due to irradiation of the abdomen has also been reduced by administration of probiotics [105] .
E. Inflammatory Bowel Disease
The heterogeneity of clinical disorders referred to as inflammatory bowel disease (IBD) comprising Crohn's disease and ulcerative colitis is striking. The etiology of IBD remains unknown, although genetic and environmental factors as well as microbial factors are well known to be involved [106, 107, 108] . The complexity of the different disease patterns implies that potential applications of probiotics should be studied extensively and with care, paying attention to the fact that strain-specific properties may be required for subset-specific categories of patients. Cocktails of probiotic strains applied at specific doses may be developed for individual use. Also, there exists a need for a more mechanistic type of research, which is indispensable to effectively select the most suitable strain for each specific patient and his condition.
-Ulcerative Colitis and Crohn's Disease
A recent concise review was prepared by Hamilton-Miller [109] . Probiotic bacteria have already been shown to counteract inflammatory processes [110] [111] [112] [113] [114] [115] [116] [117] [118] by enhancing the degradation of enteral antigens, reducing the secretion of inflammatory mediators, improving the normalization of indigenous flora and stabilizing gut barrier functions.
As a consequence, restoring of the properties of indigenous microflora by specific strains is an important rationale of probiotic therapy of IBD. The best documented strains include the VSL#3 mixture (8 strains including lactobacilli, bifidobacteria and Streptococcus) and the E. coli Nissle preparation.
-Pouchitis
As many as 50% of people who undergo surgery for ulcerative colitis will develop pouchitis. This pathology includes frequent and urgent bowel movements, abdominal cramping, bleeding and fever. Most cases of pouchitis respond well to treatment with antibiotics, but the inflammation recurs in about two thirds of patients. The exact cause of pouchitis is unknown, but has been associated with reduced levels of some bacteria normally found in the intestinal tract [119] . Gionchetti et al. [120] , tested the effects of probiotics (VSL#3 mixture) on twenty patients with chronic pouchitis and compared the relapse frequency with a "control" group of another 20 patients receiving a placebo without bacteria. After a 9 month treatment, 85% of the probiotic group was still symptom-free, while all 20 people in the placebo group relapsed within 4 months. All twenty patients of the probiotic group relapsed within 4 months following the treatment.
These positive results have encouraged other groups to organize similar trials with different probiotic strains and doses. Results should become available soon.
F. Reduction of Allergy
In recent years the hygiene hypothesis has not been abandoned [122] . Babies are born with a Th 2 biased immune response as a consequence of placental immune modulation towards feto-paternal antigens [123] . This Th 2 response (allergy promoting) is thought to be down-regulated by postnatal contact with microbial products. The initial compositional development of the intestinal flora is considered to be critical in the development of normal gut barrier functions and may be important in the normal immune modulation of the neonate [46, 49, 124] . Gut microflora directs the regulation of the immune responsiveness by affecting the development of the gutassociated lymphoid tissue (GALT) at an early age. Therefore, the use of proper microbial agents to effectively change this gut microflora, might decrease the risk for atopy. A pre-and postnatal intervention study with probiotics for children at high risk for atopic disease, has shown that probiotics significantly reduce the prevalence of atopic dermatitis in these neonates as compared to that in infants receiving placebo [125] . However, in this trial, no positive effect was observed on total IgE, specific IgE or skin test. This suggests an alternative mechanism to the modification of the Th 1 / Th 2 balance; therefore the effect of probiotics may extend well beyond this modulation of cytokine balance. Also, it cannot be expected that LAB will be efficient in reducing all forms of allergy. Recently, in a placebo controlled, double blind study, Helin et al. [121] found no effect of oral treatment with the strain Lactobacillus rhamnosus GG on birch pollen allergy.
G. Irritable Bowel Syndrome
IBS is a multifactorial gastrointestinal disorder affecting 15 -20% of the population in industrialized countries and 25-50% of all patients in gastro-enterological ambulatory services. IBS is not associated with an organic disease. Women are more sensitive than men and between 20 to 50% of the patients are finally referred to a hospital. IBS is common after gastro-enteritis or a course of antibiotics and is characterized by abdominal pain, flatulence, abdominal bloating and variable bowel habit (constipation, structural diarrhea) or even dyspepsia. Besides psycho-physiological causes, motility disturbances and colonic malfermentation have been mentioned. The latter have often been linked to an abnormal flora with increased numbers of facultative organisms such as Klebsiella spp. and enterococci and decreased numbers of lactobacilli and bifidobacteria.
Some studies with probiotics have shown improvement in pain and flatulence or in relieving constipation [126, 127] . Other studies have reported more limited benefits, often due to low levels of compliance [126] , or were not significant for all parameters tested [128] . The preventive use of probiotics against IBS gained trust in case of e.g. an antibiotic treatment. More research might be needed to identify the exact IBS-cases where probiotics can be helpful and select those probiotic strains that are most effective.
H. Colon Cancer
Colorectal cancer is the fourth commonest cause of cancer morbidity and mortality worldwide (8.9% of all new cancers, with about 400,000 deaths/year). High incidence rates are found in Western Europe, Northern America and Australia, intermediate rates in Eastern Europe, and the lowest rates found in sub-Sahara Africa. At present direct experimental evidence is lacking for suppression of cancer in humans by probiotic bacteria, but many indirect evidence have been described [129] and some mechanisms suggested [10] . These are reviewed in references [4] and [130] 
I. Traveler's Diarrhea
Although a very common problem for travelers in highrisk area, the prophylactic use of antibiotics against diarrhea is not recommended in all cases [131, 132] . Probiotics have been regarded as an alternative treatment or prevention tool. In four studies, the results were positive, while three others were not significant [133] [134] [135] [136] [137] [138] [139] . Positive effects measured included both the percentages of travelers infected and the duration of the resulting diarrhea. However, the quality and reliability of most studies is often questionable because of very low levels of compliance or the presence of large scale accidental infections, linked to a specific destination or even hotel. Therefore, more systematic and well-controlled studies are necessary before probiotics can be advised as a preventive treatment for traveler's diarrhea. Attention should be paid to the administered dose and compliance.
J. Helicobacter pylori Infection
Helicobacter pylori infection of the stomach is associated with gastritis, gastric or duodenal ulcers and possibly with gastric cancer. Although antibiotic therapy for gastritis is quite effective, eradication is not always achieved and reinfection may occur. In vitro and in vivo inhibitory effects of Helicobacter pylori are reported for several lactic acid bacteria [140] [141] [142] [143] [144] [145] [146] [147] [148] . This effect could be achieved by either viable or heat killed bacteria or the culture supernatant; eradication has, however, never been obtained [149] . Wendakoon et al. [144] tested the activity of sixty-three dairy starter cultures (single or mixed) grown in skim milk against 5 strains of Helicobacter pylori. Preliminary results revealed 25 strains with anti-Helicobacter activity belonging to the Lactobacillus casei, Lb. delbrueckii, Lb. helveticus, Lb. acidophilus and Lactococcus lactis species. Skim milk cultures showed stronger inhibition towards H. pylori than did the washed cells. Many of the cultures showed a strong synergistic action on the inhibition of this pathogen. Acids produced by the dairy lactics were only partly responsible for the inhibitory action. Bosschaert et al. [150] showed that Lactobacillus casei Shirota was capable of inhibiting in vitro growth of Helicobacter pylori NCTC11637 at pH 7.0 which was not linked to lactic acid production. In a clinical trial the urease activity was reduced in patients treated with a supernatant of Lactobacillus johnsonii La1 in combination with omeprazole [146] . In different studies, other strains have been used or other effects have been registered [146, 148, 151, 152] .
K. Viral Infections
The possible effect of probiotics on viral infections has most logically been related to a stimulating effect of the probiotic agent on the immune system of the host. Regarding the immune effects of probiotics, several mechanisms of action have been proposed, involving nonspecific immune reactions (e.g. phagocytosis by macrophages) or specific immunity (involving e.g. T4 (helper)-, T8 (cytotoxic)-or B lymphocytes producing antibodies). A lot of research has focused on the GALT (Gut-Associated Lymphoid Tissue) and at least for animals, LAB have shown to exhibit adjuvant properties [153] . Also in humans it has been shown that LAB can stimulate the production of IFN-gamma by peripheral blood lymphocytes, can increase serum IgA [154, 155] and can stimulate the phagocytic capacity of leukocytes [156] . An enhanced immune response has also been noted versus an oral vaccine against Salmonella typhi or rotavirus [157] . A second mechanism of probiotic action is related to a potential barrier effect against pathogens, often referred to as competitive exclusion.
Despite these different observations, very few welldocumented studies showing an anti-viral effect of probiotics have been published and clearly further research is necessary to confirm these preliminary results
Polio is an enterovirus and has a first multiplication step in the intestinal mucosa. A recent placebo-controlled, double blind study in healthy subjects showed that probiotics induce an immunological response and provided protection from polioviruses by increasing production of virusneutralising antibodies [158, 159] . Also recent results of a controlled, randomized double blind trial indicate that long term consumption of probiotics might reduce respiratory tract infections, including the common cold [159] .
L. Cholesterol lowering effects
Hypercholesteremia has been linked with increased risk for coronary heart disease, one of the leading causes of death today. The use of probiotics to reduce this risk seems very attractive, especially if consumed as a part of a normal daily nutrition. Although several laboratories have looked at the relation between LAB consumption and cholesterol one paper has suggested that Lb. acidophilus could remove cholesterol from laboratory media, in the presence of bile. However, Klaver and Van der Meer [160] showed that this could be due to bile salt-deconjugating activity. A few human studies have suggested a decrease of serum cholesterol concentrations during consumption of (very) large amounts (up to eight liter per day!) of yogurt or fermented milk [161] [162] [163] . However, cholesterol reduction was reported after consumption of milk as well. Andersson et al. [164] indeed suggested that the bile flow was stimulated by regular milk consumption (1 liter per day) . In other studies, the initial effect of cholesterol reduction could not be maintained until the end of the 6 weeks study period [165, 166] . De Smet et al. [167] conducted an experiment in hypercholesteremic pigs and showed a significant reduction of serum cholesterol levels after administration of a preparation of Lactobacillus reuteri.
These preliminary reports, most often not properly controlled, do not promote at this stage the use of (selected) probiotic strains to lower plasma cholesterol levels. Other functional foods have been more successfully investigated for that purpose, but fall outside the scope of this paper.
PUBLIC AND LEGAL IMPLICATIONS
The present definition of both fermented milk and probiotics emphasizes the viability of the microorganisms. However, it remains unclear whether viable bacteria are necessary for all specified health claims. A number of studies have compared the properties of viable and nonviable probiotic bacteria in applications such as improved lactose digestion, immunostimulation, anti-tumor and antimutagenic activities, anti-hypertensive or anti-cholesterol effects and protection against candiasis (for recent reviews see [24, 168] ). It is hard to draw definitive conclusions from these studies as they were generally not conducted to assess the efficacy of non-viable bacteria but rather included killed microorganisms as placebo or control. Also, different methods of cell inactivation were used and this may have influenced the results [168] . Nevertheless, it appears that cell components, enzymatic activities or metabolic / fermentation products derived from probiotic bacteria may contribute or even mediate specific health beneficial effects. For example, non-viable probiotic bacteria trigger the immune system in the same way as viable ones when given parenterally. In contrast, upon oral administration, viable micro-organisms seem to be more effective than killed ones. At present, there seems to be a general trend that, for many applications, viable preparations are more effective. Nevertheless, this would deserve to be confirmed by studies specifically set up to clarify the active ingredient mediating the studied effect, i.e. intact viable cell or cell component(s). The use of nonviable preparations would indeed offer both economic and social advantages, e.g. facilitating their use in developing countries [168] .
Accurate information on the content and counts of bacteria in commercial products is one important aspect of communication on probiotics, which nowadays remains inadequate too frequently. But the emphasis of the message addressed to the consumers obviously lies at the level of the health claims. Although most consumers will not know precisely what 'probiotic' means in a scientific sense, it is apparent that they expect special properties in a food so labeled. At present, most probiotic products are presented in the market as foodstuffs not targeted to specific populations. The labeling generally mentions inclusion of probiotic microorganisms and, eventually, includes general claims such as "contributes to health" or "influences the immune system". As stated above, it is actually forbidden by law to mislead consumers as to the true nature of the product and, currently, medicinal claims are forbidden. Regulatory and product labeling issues are the matter of active discussions in many parts on the world and the current legal situations are different in Japan, USA, Australia, New-Zealand and the European countries (for recent reviews see [17, 23, 24] ). In Japan a specific FOSHU label (Food for Specified Health Use) can be requested. FOSHU is the permission to put a health claim on a food package along with a nationally known symbol (Fig. (1) ). The Japanese Ministry of Health and Welfare hands out this authority upon the approval of a scientific dossier which fully substantiates the claim(s) made. This legislation is both beneficial to the producers, who have a way to discriminate research-supported products from "cow boy" products, as well as to the consumer, who is protected against non-approved claims. It might, therefore, be assumed that progress in the harmonization of regulatory and product labeling issues will again heavily depend on progress in science.
CONCLUSION
The interest in establishing scientific credibility for probiotic effects is of high importance to companies and scientists. Research to support health claims will have to take into account the intestinal microbiota and its interaction with the host. One of the reasons that raised skepticism in the field is the vast array of health benefits attributed to LAB strains especially and the variety or diversity of experimental approaches. The recently developed molecular technologies will certainly help in acquiring a better understanding of the complex interaction between the probiotic strain and the gut (or vaginal) ecosystem. A multidisciplinary approach, combining molecular taxonomy and biology, modern microbial ecology, immunology, gastroenterology, physiology and biochemistry, will be necessary to gain knowledge in the cross-talk that most certainly takes place between the intestinal microbes and the host cells. While unraveling of the mechanisms of action may greatly facilitate future selection of novel probiotic strains with a specific health benefit, any postulated effect will have to be definitely proven by well-conducted clinical studies. This might be easier to achieve when targeting the improvement of pathological situations.
In a climate of increasing consumer awareness that diet and health are linked, research in probiotics remains more than ever a fascinating challenge. Despite the scientific problems that still exist, many researchers in the field are gradually accepting the idea that probiotics will help many patients in the future. A number of clinicians have started to use probiotics, not as an alternative treatment, but often as an additional factor, minimizing negative aspects of traditional treatment procedures. The use of probiotics in a medical context, however, is still hampered by the relatively low number of properly registered preparations.
The formats of applications can vary between simple dietary adjustments to the therapeutic use of probiotics attempting to modify the intestinal flora in a desired way. Research efforts will need to be maintained in order to support these and possibly new applications of probiotics. Genomics and proteomics approaches will most probably help to gain insight in the cross-talk between the intestinal microflora and the host intestinal epithelium and immune system.
